Three-Year Overall Survival of Patients With Advanced Non-Small-Cell Lung Cancers With ?50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study).
Auteurs : Decroisette, C ; Greillier, L ; Curcio, H ; Pérol, M ; Ricordel, C ; Auliac, JB & al (Guisier F).
